Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flunisolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.70 |
| ▸ | AR | P10275 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunisolide SCHEMBL19681909 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13602384 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13026142 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL8810954 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL30994800 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5493687 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5187487 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13662143 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL4351 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL22527648 | 0.99 | CYP3A4 (0.98) | CYP3A4PGRNR3C1LMNAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | GENENTECH, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| EP-1613282-B1 | FORMULATIONS AND METHODS FOR TREATING RHINOSINUSITIS | MYLAN SPECIALTY L P (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9180126-B2 | Formulations and methods for treating rhinosinusitis | MYLAN SPECIALTY L.P. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9044448-B2 | X-ray contrast media compositions and methods of using the same | 3E THERAPEUTICS CORPORATION (US) | 2015-06-02 | — | — | US | disclosed |
| US-8912174-B2 | Formulations and methods for treating rhinosinusitis | MYLAN PHARMACEUTICALS INC. (US) | 2014-12-16 | — | — | US | disclosed |
| CN-1774238-B | Formulations and methods for treating rhinosinusitis | DEY L P | 2013-09-04 | — | — | CN | disclosed |
| US-20120237559-A1 | FORMULATIONS AND METHODS FOR TREATING RHINOSINUSITIS | DEY PHARMA, L.P. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8129364-B2 | Formulations and methods for treating rhinosinusitis | DEY PHARMA, L.P. (US) | 2012-03-06 | — | — | US | disclosed |
| CN-1774238-A | Formulations and methods for treating rhinosinusitis | MERCK PATENT GMBH (DE) | 2006-05-17 | — | — | CN | disclosed |
| US-20060051300-A1 | Formulations and methods for treating rhinosinusitis | MERCK PATENT GMBH | 2006-03-09 | — | — | US | disclosed |
| US-5049389-A | Non-phospholipd lipid, delivery by inhalation | LIPOSOME TECHNOLOGY, INC. (US) | 1991-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10584181-B2 | Methods of making and using multispecific antibody panels and antibody analog panels | FCGR2A, FCGR3B, FCGR1A | NR3C1 1811/4885CYP3A4 1650/4885PGR 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.